---
title: "Guggenheim Sticks to Its Hold Rating for ACADIA Pharmaceuticals (ACAD)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295012637.md"
description: "Guggenheim analyst maintained a Hold rating on ACADIA Pharmaceuticals yesterday. The company’s shares closed today at $27.15.Claim 55% Off TipRanks Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks In addition to Guggenheim, ACADIA Pharmaceuticals also received a Hold from Stifel Nicolaus’s Paul Matteis in a report issued today. However, on the same day, Citizens JMP maintained a Buy rating on ACADIA Pharmaceuticals (NASDAQ: ACAD)."
datetime: "2026-08-05T20:25:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295012637.md)
  - [en](https://longbridge.com/en/news/295012637.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295012637.md)
generator: "portal-rs"
---

# Guggenheim Sticks to Its Hold Rating for ACADIA Pharmaceuticals (ACAD)

Guggenheim analyst maintained a Hold rating on ACADIA Pharmaceuticals yesterday. The company’s shares closed today at $27.15.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

In addition to Guggenheim, ACADIA Pharmaceuticals also received a Hold from Stifel Nicolaus’s Paul Matteis in a report issued today. However, on the same day, Citizens JMP maintained a Buy rating on ACADIA Pharmaceuticals (NASDAQ: ACAD).

### Related Stocks

- [ACAD.US](https://longbridge.com/en/quote/ACAD.US.md)
- [SF.US](https://longbridge.com/en/quote/SF.US.md)
- [CFG.US](https://longbridge.com/en/quote/CFG.US.md)
- [SF-C.US](https://longbridge.com/en/quote/SF-C.US.md)
- [SFB.US](https://longbridge.com/en/quote/SFB.US.md)
- [SF-B.US](https://longbridge.com/en/quote/SF-B.US.md)
- [SF-D.US](https://longbridge.com/en/quote/SF-D.US.md)
- [CFG-I.US](https://longbridge.com/en/quote/CFG-I.US.md)
- [CFG-E.US](https://longbridge.com/en/quote/CFG-E.US.md)
- [CFG-H.US](https://longbridge.com/en/quote/CFG-H.US.md)

## Related News & Research

- [GSA Capital Partners LLP Makes New Investment in ACADIA Pharmaceuticals Inc. $ACAD](https://longbridge.com/en/news/296084900.md)
- [ACADIA Pharmaceuticals Expands DAYBUE, NUPLAZID Reach Ahead of Key Alzheimer’s Data](https://longbridge.com/en/news/295699458.md)
- [Mark Schneyer Sells 5,849 Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock](https://longbridge.com/en/news/295283718.md)
- [Acadia Pharmaceuticals CFO Mark C. Schneyer disposes of 25,141 common shares worth $730,047.52](https://longbridge.com/en/news/295281807.md)
- [Acadia Pharmaceuticals Q2 revenue rises on DAYBUE STIX demand, lifts 2026 outlook](https://longbridge.com/en/news/294866410.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**